Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab

Jose (J.C.) Villasboas Bisneto; Stephen Maxted Ansell

doi:10.1586/14737140.2016.1121812

Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab

Jose (J.C.) Villasboas Bisneto, Stephen Maxted Ansell

Hematology

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Cancer cells are able to escape surveillance from the immune system by co-opting physiologic mechanisms such as the programmed cell death-1 (PD-1) receptor pathway. Agents able to block the interaction between the PD-1 receptor and its ligands have the potential to release T cells from tumor-induced suppression and eradicate malignant cells. Nivolumab-a PD-1 inhibitor-is approved for the treatment of patients with metastatic melanoma and lung cancer. This agent has been tested in patients with advanced Hodgkin lymphoma (HL) and showed impressive results in a phase I trial. Here we review the profile of Nivolumab including its pharmacological properties, clinical efficacy and safety in patients with advanced classical HL.

Original language	English (US)
Pages (from-to)	5-12
Number of pages	8
Journal	Expert Review of Anticancer Therapy
Volume	16
Issue number	1
DOIs	https://doi.org/10.1586/14737140.2016.1121812
State	Published - Jan 2 2016

Keywords

checkpoint inhibitors
Hodgkin lymphoma
immunerelated adverse events
Immunotherapy
nivolumab
PD-1
PD-L1

ASJC Scopus subject areas

Pharmacology (medical)
Oncology

Access to Document

10.1586/14737140.2016.1121812

Fingerprint Dive into the research topics of 'Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab'. Together they form a unique fingerprint.

Cite this

@article{be14837e4ebf4c0c943ef18d4a853c71,

title = "Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab",

abstract = "Cancer cells are able to escape surveillance from the immune system by co-opting physiologic mechanisms such as the programmed cell death-1 (PD-1) receptor pathway. Agents able to block the interaction between the PD-1 receptor and its ligands have the potential to release T cells from tumor-induced suppression and eradicate malignant cells. Nivolumab-a PD-1 inhibitor-is approved for the treatment of patients with metastatic melanoma and lung cancer. This agent has been tested in patients with advanced Hodgkin lymphoma (HL) and showed impressive results in a phase I trial. Here we review the profile of Nivolumab including its pharmacological properties, clinical efficacy and safety in patients with advanced classical HL.",

keywords = "checkpoint inhibitors, Hodgkin lymphoma, immunerelated adverse events, Immunotherapy, nivolumab, PD-1, PD-L1",

author = "{Villasboas Bisneto}, {Jose (J.C.)} and Ansell, {Stephen Maxted}",

year = "2016",

month = jan,

day = "2",

doi = "10.1586/14737140.2016.1121812",

language = "English (US)",

volume = "16",

pages = "5--12",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

number = "1",

}

TY - JOUR

T1 - Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab

AU - Villasboas Bisneto, Jose (J.C.)

AU - Ansell, Stephen Maxted

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Cancer cells are able to escape surveillance from the immune system by co-opting physiologic mechanisms such as the programmed cell death-1 (PD-1) receptor pathway. Agents able to block the interaction between the PD-1 receptor and its ligands have the potential to release T cells from tumor-induced suppression and eradicate malignant cells. Nivolumab-a PD-1 inhibitor-is approved for the treatment of patients with metastatic melanoma and lung cancer. This agent has been tested in patients with advanced Hodgkin lymphoma (HL) and showed impressive results in a phase I trial. Here we review the profile of Nivolumab including its pharmacological properties, clinical efficacy and safety in patients with advanced classical HL.

AB - Cancer cells are able to escape surveillance from the immune system by co-opting physiologic mechanisms such as the programmed cell death-1 (PD-1) receptor pathway. Agents able to block the interaction between the PD-1 receptor and its ligands have the potential to release T cells from tumor-induced suppression and eradicate malignant cells. Nivolumab-a PD-1 inhibitor-is approved for the treatment of patients with metastatic melanoma and lung cancer. This agent has been tested in patients with advanced Hodgkin lymphoma (HL) and showed impressive results in a phase I trial. Here we review the profile of Nivolumab including its pharmacological properties, clinical efficacy and safety in patients with advanced classical HL.

KW - checkpoint inhibitors

KW - Hodgkin lymphoma

KW - immunerelated adverse events

KW - Immunotherapy

KW - nivolumab

KW - PD-1

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=84955186084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955186084&partnerID=8YFLogxK

U2 - 10.1586/14737140.2016.1121812

DO - 10.1586/14737140.2016.1121812

M3 - Article

C2 - 26577822

AN - SCOPUS:84955186084

VL - 16

SP - 5

EP - 12

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 1

ER -